FORM OF SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 25th, 2018 • Altimmune, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 24, 2018, between Altimmune, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Exhibit 4.4 WARRANT AGREEMENT Agreement made as of ___________, 2005 between HEALTHCARE ACQUISITION CORP., a Delaware corporation, with offices at 2116 Financial Center, 666 Walnut Street, Des Moines, Iowa 50309 (the "COMPANY"), and CONTINENTAL STOCK...Warrant Agreement • July 12th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
Exhibit 1.1 HEALTHCARE ACQUISITION CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • July 12th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 6th, 2005 • Healthcare Acquisition Corp • New York
THIS REGISTRATION RIGHTS AGREEMENT (this "Agreement") is entered into as of the ___ day of _________, 2005, by and among: HEALTHCARE ACQUISITION CORP., a Delaware corporation (the "Company"); and the undersigned parties listed under Investors on the signature page hereto (each, an "Investor" and collectively, the "Investors").
3,369,564 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,630,436 shares of Common Stock ALTIMMUNE, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 16th, 2020 • Altimmune, Inc. • Pharmaceutical preparations • New York
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • August 14th, 2017 • Altimmune, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20 between Altimmune Inc. a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
PHARMATHENE, INC. Up to $15,000,000 of Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • March 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations • New York
PharmAthene, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 20th, 2010 • Pharmathene, Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 20, 2010, between PharmAthene, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto (including its successors and assigns, the “Purchaser”).
Delivery and Payment: Delivery of the Units shall be made on or about ___________, 2005 or such later date as Maxim may advise on not less than one day's notice to the Selected Dealer, at Maxim's principal office located at 405 Lexington Avenue, 2nd...Selected Dealer Agreement • July 12th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
HEALTHCARE ACQUISITION CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • June 10th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
The undersigned, Healthcare Acquisition Corp., a Delaware corporation (“Company”), hereby confirms its agreement with Maxim Group LLC (hereinafter referred to as “you,” “Maxim” or the “Representative”) and with the other underwriters named on Schedule A hereto for which Maxim is acting as Representative (the Representative and the other Underwriters being collectively referred to herein as the “Underwriters” or, individually, an “Underwriter”) as follows:
WARRANT AGREEMENTWarrant Agreement • June 10th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
Agreement made as of ___________, 2005 between HEALTHCARE ACQUISITION CORP., a Delaware corporation, with offices at 2116 Financial Center, 666 Walnut Street, Des Moines, Iowa 50309 (the "Company"), and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, a New York corporation, with offices at 17 Battery Place, New York, New York 10004 (the "Warrant Agent").
Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Agreement is made as of ___________, 2005 by and between HEALTHCARE ACQUISITION CORP. (the "COMPANY") and CONTINENTAL STOCK TRANSFER & TRUST COMPANY (the "TRUSTEE"). WHEREAS, the Company's...Investment Management Trust Agreement • July 12th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
Exhibit 10.3 STOCK ESCROW AGREEMENT STOCK ESCROW AGREEMENT, dated as of __________, 2005 (the "AGREEMENT"), by and among HEALTHCARE ACQUISITION CORP., a Delaware corporation (the "COMPANY"), JOHN PAPPAJOHN, DERACE L. SCHAFFER, M.D., MATTHEW P.KINLEY,...Stock Escrow Agreement • July 12th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
CONFIDENTIAL David P. Wright President and Chief Executive Officer PharmAthene, Inc. One Park Place Suite 450 Annapolis, MD 21401 Dear Mr. Wright:Placement Agent Agreement • March 27th, 2009 • Pharmathene, Inc • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between Rodman & Renshaw, LLC (“Rodman” or the “Placement Agent”) and PharmAthene, Inc. (the “Company”) that Rodman shall serve, on a “best efforts” basis, as the non-exclusive placement agent (to serve as lead co-manager with Caris & Co. (“Caris”)) for the Company in connection with the proposed public offering placement (the “Placement”) of registered securities (the “Securities”) of the Company, consisting of shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and warrants (the “Warrants”) to purchase shares of the Company’s Common Stock. The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each a “Purchaser” and, collectively, the “Purchasers”), and nothing herein constitutes an agreement of the parties that Rodman would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to
COMMON STOCK PURCHASE WARRANT PHARMATHENE, INC.Common Stock Purchase Warrant • July 20th, 2010 • Pharmathene, Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six-month anniversary of the Issue Date (the “Initial Exercise Date”) and on or prior to the close of business on the six-year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from PharmAthene, Inc., a Delaware corporation (the “Company”), up to ______ shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
LEASE AGREEMENTLease Agreement • October 25th, 2013 • Pharmathene, Inc • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this 24th day of May, 2007, between ALEXANDRIA REAL ESTATE EQUITIES, INC., a Maryland corporation (“Landlord”), and SPALTUDAQ CORP., a Delaware corporation (“Tenant”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT WITH RESPECT TO THE OMITTED PORTIONS. OMITTED...License Agreement • September 24th, 2007 • Healthcare Acquisition Corp • Blank checks • Delaware
400,000 UNITS OFPurchase Option Agreement • July 12th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
THE REGISTERED HOLDER OF THIS PURCHASE OPTION, BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE OPTION, EXCEPT AS HEREIN PROVIDED, AND THE REGISTERED HOLDER OF THIS PURCHASE OPTION AGREES THAT IT WILL NOT SELL,...Purchase Option Agreement • June 10th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
THIS PURCHASE OPTION IS NOT EXERCISABLE PRIOR TO THE LATER OF (I) ______________, 2006 AND (II) THE CONSUMMATION BY HEALTHCARE ACQUISITION CORPORATION (“COMPANY”) OF A MERGER, CAPITAL STOCK EXCHANGE, ASSET ACQUISITION OR OTHER SIMILAR BUSINESS COMBINATION (“BUSINESS COMBINATION”) (AS DESCRIBED MORE FULLY IN THE COMPANY’S REGISTRATION STATEMENT (DEFINED HEREIN)). THIS PURCHASE OPTION SHALL BE VOID AFTER 5:00 P.M, NEW YORK CITY TIME, ON _____________, 2010.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 27th, 2009 • Pharmathene, Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 23, 2009, between Pharmathene, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
INVESTMENT MANAGEMENT TRUST AGREEMENTInvestment Management Trust Agreement • June 10th, 2005 • Healthcare Acquisition Corp • Blank checks • New York
This Agreement is made as of ___________, 2005 by and between HEALTHCARE ACQUISITION CORP. (the "Company") and CONTINENTAL STOCK TRANSFER & TRUST COMPANY (the "Trustee").
ContractSection 382 Rights Agreement • November 25th, 2015 • Pharmathene, Inc • Pharmaceutical preparations • Delaware
This SECTION 382 RIGHTS AGREEMENT, dated as of November 25, 2015 (this “Agreement”), is made and entered into by and between PharmAthene, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as rights agent (the “Rights Agent”).
Exhibit 10.21 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT WITH RESPECT TO THE OMITTED...Cooperative Research and Development Agreement • September 24th, 2007 • Healthcare Acquisition Corp • Blank checks
TOUnderwriting Agreement • March 31st, 2006 • Healthcare Acquisition Corp • Blank checks
BASIC TERMSEmployment Agreement • September 24th, 2007 • Healthcare Acquisition Corp • Blank checks • Maryland
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • March 11th, 2019 • Altimmune, Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 11th, 2019 • Altimmune, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 8, 2019, between Altimmune, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT WITH RESPECT TO THE OMITTED PORTIONS. OMITTED...Services Agreement • September 24th, 2007 • Healthcare Acquisition Corp • Blank checks • Delaware
EMPLOYMENT AGREEMENTEmployment Agreement • May 8th, 2013 • Pharmathene, Inc • Pharmaceutical preparations • Maryland
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this April 18, 2008 by and between Francesca Cook (the “Executive”) and PharmAthene, Inc., a Delaware corporation (the “Company”).
INCENTIVE STOCK OPTION AGREEMENT PURSUANT TO THE ALTIMMUNE, INC. 2017 OMNIBUS INCENTIVE PLANIncentive Stock Option Agreement • November 9th, 2017 • Altimmune, Inc. • Pharmaceutical preparations • Delaware
PHARMATHENE, INC. PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 10th, 2011 • Pharmathene, Inc • Pharmaceutical preparations • Massachusetts
•] Common Units, Each Consisting of One Share of Common Stock and a Warrant to Purchase One Share of Common Stock [•] Pre-Funded Units, Each Consisting of a Pre-Funded Warrant to Purchase One Share of Common Stock and a Warrant to Purchase One Share...Underwriting Agreement • September 26th, 2018 • Altimmune, Inc. • Pharmaceutical preparations • New York
Altimmune, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Roth Capital Partners, LLC (the “Underwriter”), (i) an aggregate of [•] authorized but unissued shares (the “Firm Shares”) of Common Stock, par value $0.0001 per share, of the Company (the “Common Stock”), (ii) pre-funded warrants (the “Firm Pre-Funded Warrants”) to purchase up to an aggregate of [•] shares of Common Stock at an exercise price of $0.01 per share (the “Firm Pre-Funded Warrant Shares”), and (iii) warrants (the “Firm Warrants”) to purchase up to an aggregate of [•] shares of Common Stock (the “Firm Warrant Shares”). The Firm Shares, the Firm Warrants, the Firm Pre-Funded Warrants, the Firm Pre-Funded Warrant Shares and the Firm Warrant Shares are collectively referred to as the “Firm Securities.” The Company also proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriter, (i) an aggregate of [•] a
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 3rd, 2009 • Pharmathene, Inc • Pharmaceutical preparations • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of July 28, 2009 by and among PharmAthene, Inc., a Delaware corporation (the “Company”) and the “Investors” parties hereto.
ALTIMMUNE, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • February 28th, 2023 • Altimmune, Inc. • Pharmaceutical preparations • New York
NONQUALIFIED STOCK OPTION AGREEMENT PURSUANT TO THE ALTIMMUNE, INC. 2018 INDUCEMENT GRANT PLANNonqualified Stock Option Agreement • December 3rd, 2018 • Altimmune, Inc. • Pharmaceutical preparations • Delaware
THIS NON-QUALIFIED STOCK OPTION AWARD AGREEMENT (this “Agreement”), dated as of the Grant Date specified above, is entered into by and between Altimmune, Inc., a Delaware corporation (the “Company”), and the Participant specified above, pursuant to the Altimmune, Inc. 2018 Inducement Grant Plan, as in effect and as amended from time to time (the “Plan”), which is administered by the Committee; and
